Stocks and Investing
Stocks and Investing
Tue, December 13, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Samantha Semenkow Initiated (BEAM) at Strong Buy and Held Target at $62 on, Dec 13th, 2022
Samantha Semenkow of Citigroup, Initiated "Beam Therapeutics Inc." (BEAM) at Strong Buy and Held Target at $62 on, Dec 13th, 2022.
Samantha has made no other calls on BEAM in the last 4 months.
There are 2 other peers that have a rating on BEAM. Out of the 2 peers that are also analyzing BEAM, 1 agrees with Samantha's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Richard Law of "Credit Suisse" Maintained at Hold with Decreased Target to $53 on, Tuesday, November 8th, 2022
This is the rating of the analyst that currently disagrees with Samantha
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $81 on, Monday, November 7th, 2022
Contributing Sources